PFS Improvement Seen in IMpower132 Trial for Patients With NSCLC

Vassiliki A. Papadimitrakopoulou, MD, Jay and Lori Eisenberg Distinguished Professor of Medicine and section chief of thoracic medical oncology in the department of thoracic/head and neck medical oncology at The University of Texas MD Anderson Cancer Center, discusses the data that were presented at the World Conference on Lung Cancer earlier this year for the IMpower 132 trial comparing the combination of carboplatin/cisplatin plus atezolizumab (Tecentriq) to standard chemotherapy in patients with non–small cell lung cancer.

Vassiliki A. Papadimitrakopoulou, MD, Jay and Lori Eisenberg Distinguished Professor of Medicine and section chief of thoracic medical oncology in the department of thoracic/head and neck medical oncology at The University of Texas MD Anderson Cancer Center, discusses the data that were presented at the World Conference on Lung Cancer earlier this year for the IMpower 132 trial comparing the combination of carboplatin/cisplatin plus atezolizumab (Tecentriq) to standard chemotherapy in patients with non—small cell lung cancer.

In this phase III trial, PD-L1 status was only examined in 60% of patients as tissue was not mandatory, Papadimitrakopoulou says. Patients with brain metastases were also not included in the trial.

One of 2 co-primary endpoints were met in this trial, which was progression-free survival (PFS). In terms of PFS, the combination was superior to chemotherapy alone, she said.